UK markets closed


LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
19.25-0.25 (-1.28%)
At close: 04:24PM BST


Surrey Research Park
10 Nugent Road
Guildford GU2 7AF
United Kingdom
44 14 8334 3434

IndustryDiagnostics & Research
Full-time employees173

Key executives

NameTitlePayExercisedYear born
Mr. Andrew David William Newland ACA, MengFounder, CEO & Executive Director264kN/A1961
Mr. Ian Francis Griffiths ACA, BACFO, Finance Director, Company Secretary & Executive Director164kN/A1964
Mr. Martin CookeDirector of Operations & Regulatory AffairsN/AN/A1969
Dr. Karen Miller Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Andrew John HolderHead of Investor RelationsN/AN/A1968
Ms. Anne-Sophie Pailhes-JimenezHead of R&D and Senior DirectorN/AN/AN/A
Mr. Brett SwansigerChief Commercial OfficerN/AN/AN/A
Mr. Nick ClaxtonSenior Vice President of Commercial OperationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Corporate governance

ANGLE plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.